ЛИТЕРАТУРА

1. Bousfi ha A., Jeddane L., Picard C., et al. Human inborn errors of immunity: 2019 update of the IUIS phenotypical classifi cation // J Clin Immunol. 2020. Vol. 40, N 1. Р. 66–81. doi: 10.1007/s10875-020-00758-x 
2. Tangye S.G., Al-Herz W., Bousfi ha A., et al. Human inborn errors of immunity: 2019 update on the classifi cation from the international union of immunological societies expert committee // J Clin Immunol. 2020. Vol. 40, N 1. Р. 24–64. doi: 10.1007/s10875-019-00737-x
3. World Health Organisation. Coronavirus [Internet]. Режим доступа: https://www.who.int/health-topics/coronavirus. Дата обращения: 28.08.2021.
4. Wikipedia. Template: COVID-19 pandemic data [Internet]. Режим доступа: https://en.wikipedia.org/wiki/ Template:COVID-19_pandemic_data. Дата обращения: 28.08.2021.
5. World Health Organisation. Coronavirus disease (COVID-19): vaccines [Internet]. Режим доступа: https:// www.who.int/news-room/q-a-detail/coronavirusdisease-(covid-19)-vaccines. Дата обращения: 28.08.2021.
6. Goudouris E.S., Pinto-Mariz F., Mendonça L.O., et al. Outcome of SARS-CoV-2 Infection in 121 patients with inborn errors of immunity: a cross-sectional study // J Clin Immunol. 2021. Р. 1–11. doi: 10.1007/s10875-021-01066-8
7. Goldacker S., Draeger R., Warnatz K., et al. Active vaccination in patients with common variable immunodefi ciency (CVID) // Clin Immunol. 2007. Vol. 124, N 3. Р. 294–303. doi: 10.1016/j.clim.2007.04.011
8. Pedersen G., Halstensen A., Sjursen H., et al. Pandemic infl uenza vaccination elicits infl uenza-specifi c CD4+ Th1-cell responses in hypogammaglobulinaemic patients: four case reports // Scand J Immunol. 2011. Vol. 74, N 2. Р. 210–218. doi: 10.1111/j.1365-3083.2011.02561.x
9. Rezaei N., Siadat S.D., Aghamohammadi A., et al. Serum bactericidal antibody response 1 year after meningococcal polysaccharide vaccination of patients with common variable immunodefi ciency // Clin Vaccine Immunol. 2010. Vol. 17, N 4. Р. 524–528. doi: 10.1128/CVI.00389-09
10. Hanitsch L.G., Löbel M., Mieves J.F., et al. Cellular and humoral infl uenza-specifi c immune response upon vaccination in patients with common variable immunodefi ciency and unclassifi ed antibody defi ciency // Vaccine. 2016. Vol. 34, N 21. Р. 2417–2423. doi: 10.1016/j.vaccine.2016.03.091
11. Paroli M., Accapezzato D., Francavilla V., et al. Long-lasting memory-resting and memory-eff ector CD4+T cells in human X-linked agammaglobulinemia // Blood. 2002. Vol. 99, N 6. Р. 2131–2137. doi: 10.1182/blood.v99.6.2131
12. IPOPI. Vaccination against SARS-COV-2 (COVID-19) for patients with PID [Internet]. Режим доступа: https://ipopi.org/latest-news-on-covid-19-and-pid-1/. Дата обращения: 28.08.2021.
13. Marciano B.E., Huang C.Y., Joshi G., et al. BCG vaccination in patients with severe combined immunodefi ciency: complications, risks, and vaccination policies // J Allergy Clin Immunol. 2014. Vol. 133, N 4. Р. 1134–1141. doi: 10.1016/j.jaci.2014.02.028
14. Shearer W.T., Fleisher T.A., Buckley R.H., et al. Recommendations for live viral and bacterial vaccines in immunodefi cient patients and their close contacts // J Allergy Clin Immunol. 2014. Vol. 133, N 4. Р. 961–966. doi: 10.1016/j.jaci.2013.11.043
15. Shaghaghi M., Shahmahmoodi S., Abolhassani H., et al. Vaccine-derived polioviruses and children with primary immunodefi ciency, Iran, 1995–2014 // Emerg Infect Dis. 2016. Vol. 22, N 10. Р. 1712–1719. doi: 10.3201/eid2210.151071
16. Государственный реестр лекарственных средств. Регистрационное удостоверение. Инструкция к вакцине КовиВак (Вакцина коронавирусная инактивирован- ная цельновирионная концентрированная очищенная) [Internet]. Режим доступа: https://grls.rosminzdrav.ru/ Grls_View_v2.aspx?routingGuid=2b6c0483-705d-4b51- a722-2b954a9f918d&t=. Дата обращения: 28.08.2021.
17. Государственный реестр лекарственных средств. Регистрационное удостоверение. Инструкция к вакцине Гам-КОВИД-Вак (Комбинированная векторная вакцина для профилактики коронавирусной инфекции, вызываемой вирусом SARS-CoV-2) [Internet]. Режим доступа: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=7d85c1ea-a7f8-43e5-8975-a4827ee5d88a&t=. Дата обращения: 28.08.2021.
18. Государственный реестр лекарственных средств. Регистрационное удостоверение. Инструкция к вакцине ЭпиВакКорона (Вакцина на основе пептидных антигенов для профилактики COVID-19 [Internet]. Режим доступа: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=35c6fdb8-821b-4f69-b566- f6245ad1f437&t=. Дата обращения: 28.08.2021.
19. Государственный реестр лекарственных средств. Регистрационное удостоверение. Инструкция к препарату Спутник Лайт (Векторная вакцина для профилактики коронавирусной инфекции, вызываемой вирусом SARSCoV-2 [Internet]. Режим доступа: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=3783532a-0d9f-4e2e89c3-9c5a6fa32688&t=. Дата обращения: 28.08.2021.
20. Eibl M.M., Wolf H.M. Vaccination in patients with primary immune defi ciency, secondary immune defi ciency and autoimmunity with immune regulatory abnormalities // Immunotherapy. 2015. Vol. 7, N 12. Р. 1273–1292. doi: 10.2217/IMT.15.74
21. Hagin D., Freund T., Navon M., et al. Immunogenicity of Pfi zer-BioNTech COVID-19 vaccine in patients with inborn errors of immunity // J Allergy Clin Immunol. 2021. Vol. 148, N 3. Р. 739–749. doi: 10.1016/j.jaci.2021.05.029
22. Ameratunga R., Longhurst H., Steele R., et al. Common variable immunodefi ciency disorders, T cell responses to SARSCoV-2 vaccines and the risk of Chronic COVID-19 // J Allergy Clin Immunol Pract. 2021. Vol. S2213-2198, N 21. Р. 00702–00709. doi: 10.1016/j.jaip.2021.06.019
23. Временные методические рекомендации. Порядок проведения вакцинации взрослого населения против COVID-19. Москва, 2021. 50 с.
24. Латышева Т.В., Латышева Е.А., Манто И.А., Костинова А.М. Вакцинация больных с первичными иммунодефицитами: современный взгляд на проблему // Российский аллергологический журнал. 2017. Т. 14, № 3. С. 19–26.
25. Близнец Е.А., Викторова Е.А., Вишнева Е.А., и др. Наследственный ангиоотек. Клинические рекомендации // Российский аллергологический журнал. 2021. Т. 18, № 2. С. 77–114. doi: 10.36691/RJA1447

REFERENCES

1. Bousfi ha A, Jeddane L, Picard C, et al. Human inborn errors of immunity: 2019 update of the IUIS phenotypical classifi cation. J Clin Immunol. 2020;40(1):66–81. doi: 10.1007/s10875-020-00758-x
2. Tangye SG, Al-Herz W, Bousfi ha A, et al. Human inborn errors of immunity: 2019 update on the classifi cation from the international union of immunological societies expert committee. J Clin Immunol. 2020;40(1):24–64. doi: 10.1007/s10875-019-00737-x 
3. World Health Organisation. Coronavirus [Internet]. Available from: https://www.who.int/health-topics/coronavirus. Accessed: Aug 28, 2021.
4. Wikipedia. Template: COVID-19 pandemic data [Internet]. Available from: https://en.wikipedia.org/wiki/ Template:COVID-19_pandemic_data. Accessed: Aug 28, 2021.
5. World Health Organisation. Coronavirus disease (COVID-19): vaccines [Internet]. Available from: https:// www.who.int/news-room/q-a-detail/coronavirus-disease-(covid-19)-vaccines. Accessed: Aug 28, 2021.
6. Goudouris ES, Pinto-Mariz F, Mendonça LO, et al. Outcome of SARS-CoV-2 Infection in 121 patients with inborn errors of immunity: a cross-sectional study. J Clin Immunol. 2021;1–11. doi: 10.1007/s10875-021-01066-8
7. Goldacker S, Draeger R, Warnatz K, et al. Active vaccination in patients with common variable immunodefi - ciency (CVID). Clin Immunol. 2007;124(3):294–303. doi: 10.1016/j.clim.2007.04.011
8. Pedersen G, Halstensen A, Sjursen H, et al. Pandemic № CD4+ Th1-cell responses in hypogammaglobulinaemic patients: four case reports. Scand J Immunol. 2011;74(2):210– 218. doi: 10.1111/j.1365-3083.2011.02561.x
9. Rezaei N, Siadat SD, Aghamohammadi A, et al. Serum bactericidal antibody response 1 year after meningococcal polysaccharide vaccination of patients with common variable immunodefi ciency. Clin Vaccine Immunol. 2010;17(4):524–528. doi: 10.1128/CVI.00389-09
10. Hanitsch LG, Löbel M, Mieves JF, et al. Cellular and humoral infl uenza-specifi c immune response upon vaccination in patients with common variable immunodefi ciency and unclassifi ed antibody defi ciency. Vaccine. 2016;34(21):2417– 2423. doi: 10.1016/j.vaccine.2016.03.091
11. Paroli M, Accapezzato D, Francavilla V, et al. Long-lasting memory-resting and memory-eff ector CD4+T cells in human X-linked agammaglobulinemia. Blood. 2002;99(6):2131– 2137. doi: 10.1182/blood.V99.6.2131
12. IPOPI. Vaccination against SARS-COV-2 (COVID-19) for patients with PID [Internet]. Available from: https://ipopi.org/latest-news-on-covid-19-and-pid-1/. Accessed: Aug 28, 2021.
13. Marciano BE, Huang CY, Joshi G, et al. BCG vaccination in patients with severe combined immunodefi ciency: complications, risks, and vaccination policies. J Allergy Clin Immunol. 2014;133(4):1134–1141. doi: 10.1016/j.jaci.2014.02.028
14. Shearer WT, Fleisher TA, Buckley RH, et al. Recommendations for live viral and bacterial vaccines in immunodefi cient patients and their close contacts. J Allergy Clin Immunol. 2014;133(4):961–966. doi: 10.1016/j.jaci.2013.11.043
15. Shaghaghi M, Shahmahmoodi S, Abolhassani H, et al. Vaccine-derived polioviruses and children with primary immunodefi ciency, Iran, 1995–2014. Emerg Infect Dis. 2016;22(10):1712–1719. doi: 10.3201/eid2210.151071
16. The State Register of Medicines. Registration certifi cate. Instructions for the KoviVak vaccine (inactivated whole-virion concentrated purifi ed coronavirus vaccine) [Internet]. (In Russ). Available from: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=2b6c0483-705d-4b51-a722-2b954a9f918d&t=. Accessed: Aug 28, 2021.
17. The State Register of Medicines. Registration certifi cate. Instructions for the Gam-COVID-Vac vaccine (Combined vector vaccine for the prevention of coronavirus infection caused by the SARS-CoV-2 virus) [Internet]. (In Russ). Available from: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=7d85c1ea-a7f8-43e5-8975-a4827ee5d88a&t=. Accessed: Aug 28, 2021.
18. The State Register of Medicines. Registration certifi cate. Instructions for the EpiVacCorona vaccine (A vaccine based on peptide antigens for the prevention of COVID-19 [Internet]. (In Russ). Available from: https://grls.rosminzdrav. ru/Grls_View_v2.aspx?routingGuid=35c6fdb8-821b-4f69-b566-f6245ad1f437&t=. Accessed: Aug 28, 2021.
19. The State Register of Medicines. Registration certifi - cate. Instructions for the drug Sputnik Light (Vector vaccine for the prevention of coronavirus infection caused by the SARS-CoV-2 virus [Internet]. (In Russ). Available from: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=bd9750c9-178d-47cb-81e0-5e532219eebb&t=. Accessed: Aug 28, 2021.
20. Eibl MM, Wolf HM. Vaccination in patients with primary immune deficiency, secondary immune deficiency and autoimmunity with immune regulatory abnormalities. Immunotherapy. 2015;7(12):1273–1292. doi: 10.2217/IMT.15.74
21. Hagin D, Freund T, Navon M, et al. Immunogenicity of pfi zer-biontech COVID-19 vaccine in patients with inborn errors of immunity. J Allergy Clin Immunol. 2021;148(3):739–749. doi: 10.1016/j.jaci.2021.05.029
22. Ameratunga R, Longhurst H, Steele R, et al. Common variable immunodefi ciency disorders, T cell responses to SARSCoV-2 vaccines and the risk of Chronic COVID-19. J Allergy Clin Immunol Pract. 2021;S2213-2198(21):00702–00709. doi: 10.1016/j.jaip.2021.06.019
23. Temporary methodological recommendations. The procedure for vaccination of the adult population against COVID-19. Moscow; 2021. 50 p. (In Russ).
24. Latysheva TV, Latysheva EA, Manto IA, Kostinova AM. Vaccination of patients with primary immunodefi ciency: a modern view of the problem. Russian Journal of Allergy. 2017;14(3):19–26. (In Russ).
25. Bliznec EA, Viktorova EA, Vishneva EA, et al. Hereditary angioedema. Clinical recommendations. Russian Journal of Allergy. 2021;18(2):77–114. (In Russ). doi: 10.36691/RJA1447